British Journal of Cancer · 2015 · 171 citations · 33 references
MedicineMolecular MedicineOncologyGastrointestinal OncologyMolecular OncologyNeoplasiaCancer Molecular PathologyColorectal CancerLiver MetastasisMalignant NeoplasmsNext-generation Sequencing In OncologyRas Family OncogenesColorectal Cancer PrognosisColorectal Liver MetastasisMolecular Prognostic MarkersOncogenic Ras MutationsPrognostic Factors AnalysisPrognostic Tumor MarkersPrognostic VariablesRelapse-free Survival
BACKGROUND: Despite major advances in the management of metastatic colorectal cancer (mCRC) with liver-only involvement, relapse rates are high and reliable prognostic markers are needed. METHODS: To assess the prognostic impact of BRAF and RAS mutations in a large series of liver-resected patients, medical records of 3024 mCRC patients were reviewed. Eligible cases undergoing potentially curative liver resection were selected. BRAF and RAS mutational status was tested on primary and/or metastases by means of pyrosequencing and mass spectrometry genotyping assay. Primary endpoint was relapse-free survival (RFS). RESULTS: In the final study population (N=309) BRAF mutant, RAS mutant and all wild-type (wt) patients were 12(4%), 160(52%) and 137(44%), respectively. Median RFS was 5.7, 11.0 and 14.4 months respectively and differed significantly (Log-rank, P=0.043). At multivariate analyses, BRAF mutant had a higher risk of relapse in comparison to all wt (multivariate hazard ratio (HR)=2.31; 95% CI, 1.09-4.87; P=0.029) and to RAS mutant (multivariate HR=2.06; 95% CI, 1.02-4.14; P=0.044). Similar results were obtained in terms of overall survival. Compared with all wt patients, RAS mutant showed a higher risk of death (HR=1.47; 95% CI, 1.05-2.07; P=0.025), but such effect was lost at multivariate analyses. CONCLUSIONS: BRAF mutation is associated with an extremely poor median RFS after liver resection and with higher probability of relapse and death. Knowledge of BRAF mutational status may optimise clinical decision making in mCRC patients potentially candidate to hepatic surgery. RAS status as useful marker in this setting might require further studies.
33
Clinical Score for Predicting Recurrence After Hepatic Resection for Metastatic Colorectal Cancer
Yuman Fong, Joseph G. Fortner, Ruth L. Sun et al. · Annals of Surgery · 1999 · 3.7K citations · Full text
Panitumumab–FOLFOX4 Treatment and <i>RAS</i> Mutations in Colorectal Cancer
Jean‐Yves Douillard, Kelly S. Oliner, Salvatore Siena et al. · New England Journal of Medicine · 2013 · 2.2K citations · Full text
Medicine, Oncology, Pharmacology +15